Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Daniele Frisone"'
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Lung cancer is the leading cause of cancer mortality worldwide. Immunotherapy has demonstrated clinically significant benefit for non-small-cell lung cancer, but innate (primary) or acquired resistance remains a challenge. Criteria for a uniform clin
Externí odkaz:
https://doaj.org/article/8a6c571361654beaa6ee5108b7a3d2ea
Autor:
Alessandro Cucchetti, Benjamin Djulbegovic, Stefano Crippa, Iztok Hozo, Monica Sbrancia, Athanasios Tsalatsanis, Cecilia Binda, Carlo Fabbri, Roberto Salvia, Massimo Falconi, Giorgio Ercolani, Sergio Alfieri, Arnaldo Amato, Marco Amisano, Andrea Anderloni, Antonio Maestri, Chiara Coluccio, Giovanni Brandi, Andrea Casadei-Gardini, Vincenzo Cennamo, Stefano Francesco Crinò, Raffaele Dalla Valle, Claudio De Angelis, Monica Di Battista, Massimo Di Maio, Mariacristina Di Marco, Marco Di Marco, Francesco Di Matteo, Roberto Di Mitri, Giuseppe Maria Ettorre, Antonio Facciorusso, Gabriella Farina, Giovanni Ferrari, Lorenzo Fornaro, Isabella Frigerio, Daniele Frisone, Lorenzo Fuccio, Andrea Gardini, Carlo Garufi, Riccardo Giampieri, Gian Luca Grazi, Elio Jovine, Emanuele Kauffmann, Serena Langella, Alberto Larghi, Mauro Manno, Emanuele Marciano, Marco Marzioni, Alberto Merighi, Massimiliano Mutignani, Bruno Nardo, Monica Niger, Valentina Palmisano, Stefano Partelli, Carmine Pinto, Enrico Piras, Ilario Giovanni Rapposelli, Michele Reni, Claudio Ricci, Lorenza Rimassa, Salvatore Siena, Cristiano Spada, Elisa Sperti, Mariangela Spezzaferro, Carlo Sposito, Stefano Tamberi, Roberto Troisi, Luigi Veneroni, Marco Vivarelli, Alessandro Zerbi
Publikováno v:
Surgery. 173:1421-1427
Autor:
Daniele Frisone, Pierre O. Chappuis
Publikováno v:
Praxis. 112:184-188
Abstract. Dermatologic and rheumatologic toxicities are frequent adverse events during treatment with immune checkpoint inhibitors in oncology. Timely identification of these events and the referral to the oncologist or dermatologist are important in
Autor:
Luc E. Barberini, Niels Gobin, Sonaz Malekzadeh, Christophe Constantin, Philippe Renard, Daniele Frisone
Publikováno v:
International Journal of Surgery Oncology. 5:e941-e944
Autor:
Sophie Clément, Pierre O. Chappuis, Alexandre Bodmer, Krisztian Homicsko, Yann Christinat, Melinda Charrier, Olivier Michielin, Petros Tsantoulis, Daniele Frisone, Thomas Alexander Mckee, Laure Thouvenin
Publikováno v:
Cancer biology & therapy, vol. 21, no. 3, pp. 197-202
Cancer Biology and Therapy, Vol. 21, No 3 (2020) pp. 197-202
Cancer Biology and Therapy, Vol. 21, No 3 (2020) pp. 197-202
Alterations of the Retinoblastoma (Rb) pathway are frequent in ovarian cancer, typically resulting from CDKN2A down-regulation, CCNE1 amplification, CCND1/2 amplification, and RB1 loss. However, bi-allelic CDKN2A mutation or homozygous deletion is a
Publikováno v:
Current Oncology Reports
Purpose of Review There has been a huge development in the assessment of malignancies through liquid biopsies last years, especially for NSCLC, where its use has become part of clinical practice in some settings. We aim to summarize current evidence
Publikováno v:
Cancer Epidemiology. 80:102232
Using US population-level data, it has been suggested that novel treatment advances, particularly targeted therapies, have contributed to a sharp fall in NSCLC mortality. Switzerland is a high-income country, with a universal, highly performant healt
Publikováno v:
Critical reviews in oncology/hematology. 152
BRAF is a rare targetable mutation in non-small-cell lung cancer (NSCLC). Emerging evidence underlines that, rather than a single point mutation, BRAF genes present with a wide array of mutations, essentially in lung adenocarcinoma. Different BRAF mu
Autor:
Daniele, Frisone, Melinda, Charrier, Sophie, Clement, Yann, Christinat, Laure, Thouvenin, Krisztian, Homicsko, Olivier, Michielin, Alexandre, Bodmer, Pierre O, Chappuis, Thomas A, McKee, Petros, Tsantoulis
Publikováno v:
Cancer Biology & Therapy
Alterations of the Retinoblastoma (Rb) pathway are frequent in ovarian cancer, typically resulting from CDKN2A down-regulation, CCNE1 amplification, CCND1/2 amplification, and RB1 loss. However, bi-allelic CDKN2A mutation or homozygous deletion is a
Autor:
Adriana, Iacob Popescu, Liz, Coronado, Aikaterini, Efstathopoulou, Daniele, Frisone, Gian-Marco, Stamm, Javier, Torralvo, Luc, Barberini, Pierre-Auguste, Petignat
Publikováno v:
Revue medicale suisse. 12(529)
Daily medical practice triggers reflexes in the use of drugs which must nevertheless always be adapted to new knowledge. Physician assistants and residents in the clinical ward of Internal Medicine of Sion Hospital summarize six recently published cl